That can translate into meaningful weight reduction over time
Dexcoms revenue has grown significantly from $1.0 billion in 2018 to $3.6 billion in 2023, or a 29% CAGR
We look forward to advancing our mission to deliver innovative therapies with the potential to meaningfully improve the lives of people around the world needing highly effective, sustainable weight loss. The presentation is accessible on the Scientific Publications section of the Kailera website
The question that arises is no longer, "Does it work? But, "Who owns the next generation mechanism? Were likely entering a phase where: Large-cap pharma consolidates metabolic platforms Mid-cap biotech becomes an acquisition target (mechanism-driven) Valuations increasingly reflect mechanism optionality, not single indications And importantly: The winners may not be the first GLP-1 players But those building next-gen metabolic architectures Bottom line: If GLP-1 were the opening trade, multi-pathway metabolic drugs may represent the full cycle
Semaglutide, ook bekend als de werkzame stof in Ozempic en Rybelsus, is een medicijn dat wordt gebruikt voor de behandeling van type 2 diabetes en obesitas
Clinical trials have shown significant weight loss outcomes in appropriate patients, though individual results vary
